论文部分内容阅读
目的对比小剂量瑞替普酶与重组链激酶分别联合替罗非班治疗急性ST段抬高性心肌梗死的临床疗效安全性。方法将208例急性ST段抬高性心肌梗死患者随机分为研究组和对照组各104例,研究组采用小剂量瑞替普酶联合替罗非班进行治疗,对照组采用重组链激酶联合替罗非班进行治疗,治疗结束后观察2组患者的血管再通率,病死率出现不良反应情况及心血管并发症情况。结果研究组患者在溶栓后60min和90min时血管再通率均显著优于对照组(P<0.05),溶栓治疗后4周内2组心血管并发症、血管再闭塞的发生率和病死率比较差异均无统计学意义(P>0.05),研究组出血率高于对照组,差异有统计学意义(P<0.05)。结论小剂量瑞替普酶联合替罗非班与重组链激酶联合替罗非班在治疗急性ST段抬高性心肌梗死中均具有安全性,但小剂量瑞替普酶联合替罗非班的治疗效果更佳。
Objective To compare the clinical efficacy and safety of low dose reteplase and recombinant streptokinase combined with tirofiban in the treatment of acute ST-segment elevation myocardial infarction. Methods A total of 208 patients with acute ST-elevation myocardial infarction were randomly divided into study group (104 cases) and control group (104 cases). The study group was treated with low-dose reteplase combined with tirofiban, while the control group was treated with recombinant streptokinase Luo Fei Ban for treatment, after treatment, observed in two groups of patients recanalization rate, mortality and adverse reactions and cardiovascular complications. Results In the study group, the rate of recanalization at 60 min and 90 min after thrombolysis was significantly better than that of the control group (P <0.05). The incidence of cardiovascular complications and the incidence of recanalization and death within two weeks after thrombolysis (P> 0.05). The bleeding rate in study group was higher than that in control group, the difference was statistically significant (P <0.05). Conclusion Low-dose reteplase combined with tirofiban and recombinant streptokinase combined with tirofiban is safe in the treatment of acute ST-elevation myocardial infarction. However, low-dose reteplase combined with tirofiban The treatment effect is better.